166 related articles for article (PubMed ID: 36680226)
1. Before Direct-Acting Antivirals for Hepatitis C Virus: Evaluation of Core Protein R70Q and L/C91M Substitutions in Chronically Infected Brazilian Patients Unresponsive to IFN and/or RBV.
Campos LB; de Almeida NAA; de Santana CG; Barbosa ENP; Horta MAP; Amendola Pires M; Brandão Mello CE; de Paula VS; de Barros JJF
Viruses; 2023 Jan; 15(1):. PubMed ID: 36680226
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of amino acid mutations in hepatitis C virus core and NS5B regions among Venezuelan viral isolates and comparison with worldwide isolates.
Jaspe RC; Sulbarán YF; Sulbarán MZ; Loureiro CL; Rangel HR; Pujol FH
Virol J; 2012 Sep; 9():214. PubMed ID: 22995142
[TBL] [Abstract][Full Text] [Related]
3. Impact of amino acid substitutions in hepatitis C virus core region on the severe oxidative stress.
Chida T; Watanabe S; Ohta K; Noritake H; Ito M; Suzuki T; Suda T; Kawata K
Free Radic Biol Med; 2024 Feb; 212():199-206. PubMed ID: 38103659
[TBL] [Abstract][Full Text] [Related]
4. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Hepatol; 2007 Mar; 46(3):403-10. PubMed ID: 17126448
[TBL] [Abstract][Full Text] [Related]
5. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
6. Impact of hepatitis C virus core mutations on the response to interferon-based treatment in chronic hepatitis C.
Sultana C; Oprişan G; Teleman MD; Dinu S; ; Oprea C; Voiculescu M; Ruta S
World J Gastroenterol; 2016 Oct; 22(37):8406-8413. PubMed ID: 27729747
[TBL] [Abstract][Full Text] [Related]
7. Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study.
Boglione L; Cardellino CS; Cusato J; De Nicolò A; Cariti G; Di Perri G; D'Avolio A
Infect Genet Evol; 2017 Jul; 51():167-172. PubMed ID: 28315743
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Sofosbuvir Plus Ribavirin Treatment with Pegylated Interferon Plus Ribavirin Treatment for Chronic Hepatitis C Genotype 2.
Seo K; Kim SK; Kim SR; Ohtani A; Kobayashi M; Kato A; Morimoto E; Saijo Y; Kim KI; Imoto S; Kim CW; Yano Y; Kudo M; Hayashi Y
Dig Dis; 2017; 35(6):541-547. PubMed ID: 29040986
[TBL] [Abstract][Full Text] [Related]
9. Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b.
Yoshizawa K; Abe H; Aida Y; Ishiguro H; Ika M; Shimada N; Tsubota A; Aizawa Y
J Med Virol; 2013 Jul; 85(7):1180-90. PubMed ID: 23918536
[TBL] [Abstract][Full Text] [Related]
10. Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy.
El-Shamy A; Shoji I; Kim SR; Ide Y; Imoto S; Deng L; Yoon S; Fujisawa T; Tani S; Yano Y; Seo Y; Azuma T; Hotta H
PLoS One; 2012; 7(2):e30513. PubMed ID: 22319571
[TBL] [Abstract][Full Text] [Related]
11. Amino acid sequence analysis in patients with chronic HCV genotype 1b infection during pegylated interferon-α2a and ribavirin therapy.
Fu JJ; Kong WJ; Jiang D; Pan XC; Wei L
Antivir Ther; 2014; 19(7):661-8. PubMed ID: 24584067
[TBL] [Abstract][Full Text] [Related]
12. Consensus guidelines for the management of hepatitis C infection.
Consensus Guidelines Committee for the Management of Hepatitis C Infection
Saudi Med J; 2003 Jul; 24 Suppl 2():S99-118. PubMed ID: 25121186
[TBL] [Abstract][Full Text] [Related]
13. Treatment of hepatitis C virus genotype 3-infection.
Pol S; Vallet-Pichard A; Corouge M
Liver Int; 2014 Feb; 34 Suppl 1():18-23. PubMed ID: 24373074
[TBL] [Abstract][Full Text] [Related]
14. The incidence and risk factors for the development of hepatocellular carcinoma after peginterferon plus ribavirin therapy for chronic hepatitis C.
Dohmen K; Kawano A; Takahashi K; Shigematsu H; Tanaka H; Haruno M; Yanagita K; Ichiki Y; Mori T; Hayashida K; Shimoda S; Ishibashi H; Nomura H
Hepatogastroenterology; 2013; 60(128):2034-8. PubMed ID: 24719946
[TBL] [Abstract][Full Text] [Related]
15. Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C.
Welch NM; Jensen DM
Liver Int; 2015 Jan; 35 Suppl 1():11-7. PubMed ID: 25529082
[TBL] [Abstract][Full Text] [Related]
16. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
Asselah T; Marcellin P
Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
[TBL] [Abstract][Full Text] [Related]
17. Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin.
Murakami E; Imamura M; Hayes CN; Abe H; Hiraga N; Honda Y; Ono A; Kosaka K; Kawaoka T; Tsuge M; Aikata H; Takahashi S; Miki D; Ochi H; Matsui H; Kanai A; Inaba T; McPhee F; Chayama K
Antimicrob Agents Chemother; 2014; 58(4):2105-12. PubMed ID: 24468783
[TBL] [Abstract][Full Text] [Related]
18. Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: data mining analysis.
Kurosaki M; Sakamoto N; Iwasaki M; Sakamoto M; Suzuki Y; Hiramatsu N; Sugauchi F; Tamori A; Nakagawa M; Izumi N
J Med Virol; 2011 Mar; 83(3):445-52. PubMed ID: 21264865
[TBL] [Abstract][Full Text] [Related]
19. Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection.
Alestig E; Arnholm B; Eilard A; Lagging M; Nilsson S; Norkrans G; Wahlberg T; Wejstål R; Westin J; Lindh M
BMC Infect Dis; 2011 May; 11():124. PubMed ID: 21569441
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma.
Sugimoto K; Kim SR; Kim SK; Imoto S; Tohyama M; Kim KI; Ohtani A; Hatae T; Yano Y; Kudo M; Hayashi Y
Oncology; 2015; 89 Suppl 2():42-6. PubMed ID: 26584035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
